N-Acetyl Selank Amidate
Stabilized analog of Selank with N-terminal acetylation and C-terminal amidation — designed to resist enzymatic degradation, extending half-life 2-3× over standard Selank for more potent anxiolytic and nootropic effects.
🔬 Mechanism of Action
N-Acetyl Selank Amidate (NASA) is a chemically modified version of Selank — the Russian-approved anxiolytic heptapeptide. Two modifications make it superior: N-terminal acetylation blocks aminopeptidase degradation, and C-terminal amidation blocks carboxypeptidase attack. These changes extend the half-life from ~3 minutes (native Selank) to 60-90 minutes.
The core mechanism is identical to Selank: it stabilizes enkephalins (endogenous opioid peptides) by inhibiting the enzymes that degrade them, leading to increased GABAergic tone and anxiolysis without sedation. Simultaneously, it upregulates BDNF and trkB receptor expression in the hippocampus, producing genuine nootropic effects.
Unlike benzodiazepines, N-Acetyl Selank Amidate does not directly modulate GABA-A receptors and therefore produces no tolerance, dependence, or withdrawal. The mechanism is upstream — enhancing endogenous anxiolytic tone rather than forcing receptor activation.
Source: Based on PMID: 18577766
📜Background & History
N-Acetyl Selank Amidate (NASA) is a chemically stabilized version of Selank — the anxiolytic heptapeptide approved in Russia since 2009. Two chemical modifications solve Selank's major pharmacokinetic weakness: its ~3 minute half-life. N-terminal acetylation blocks aminopeptidase degradation, C-terminal amidation blocks carboxypeptidase attack, extending half-life to 60-90 minutes. This makes intranasal dosing practical — one dose provides sustained CNS effects for hours instead of minutes.
🎯 Research Use Cases
- ✓Anxiolysis without benzodiazepine-class side effects (sedation, dependence, amnesia)
- ✓Cognitive enhancement via BDNF and NGF upregulation
- ✓Stress resilience and emotional regulation
- ✓Complement to psychotherapy for generalized anxiety
💉 Dosing Protocol
| Typical Dose | 250-750 mcg/day (intranasal) |
| Frequency | 1-2× daily |
| Half-Life | ~60-90 minutes |
| Common Vial Sizes | 5 mg, 10 mg |
🧪 Reconstitution Example
⚠️Safety & Considerations
Excellent safety profile inherited from Selank (30+ years Russian clinical use). No sedation, dependence, or withdrawal. May potentiate effects of existing anxiolytic medications. Intranasal route preferred for CNS delivery. Avoid combining with MAO inhibitors.
⚡Interactions & Contraindications
May potentiate existing anxiolytic medications (benzodiazepines, SSRIs). Avoid combining with MAO inhibitors — risk of serotonergic interactions. Intranasal delivery bypasses first-pass metabolism — onset faster than subcutaneous. No tolerance, dependence, or withdrawal documented.
🔗Synergies & Common Stacks
Selank (anxiolytic + GABA-focused) pairs naturally with Semax (nootropic + dopaminergic). Together they provide comprehensive cognitive-emotional optimization — a classic Russian peptide stack.
Pinealon supports sleep architecture while NASA provides daytime anxiolysis — complementary chronobiological support without pharmacological overlap.